罗库溴铵和阿曲库铵联合应用的肌松效应分析

目的探讨罗库溴铵和阿曲库铵联合应用时的肌松效应。方法择期全麻手术女性成年患者147例,丙泊酚和舒芬太尼静脉诱导,输注丙泊酚维持麻醉。面罩辅助或控制呼吸,用加速度仪以连续4次刺激(TOF)方式透皮刺激腕部尺神经,获取肌松药作用起效时间和T1最大抑制程度(Tmax)。按观测项目将患者均分成四组。结果阿曲溴铵ED95为(220.8±3.6)μg/kg,罗库溴铵ED95为(286.3±3.1)μg/kg。0.5×ED95的罗库溴铵与阿曲库铵联合使用,肌松效应达到T1抑制93%~97%时,阿曲库铵的剂量为63.6μg/kg。罗库溴铵0.5×ED95与阿曲库铵63.6μg/kg联合使用,Tmax为(95.3±0.9)%,变异系数1.0%。Ⅳ组中三个亚组的Tmax基本相同,合用组作用起效时间比阿曲库铵组快(P<0.01)。给予肌松药前和注药后5min内,MAP和HR的波动幅度均小于5%。结论罗库溴铵与阿曲库铵合用呈协同作用。当罗库溴铵剂量为0.5×ED95时,为获得T1抑制95%的肌松效应,阿曲库铵的合理用量为63.6μg/kg,比阿曲库铵的ED95减少71.2%。     

Comparison of the haemodynamic effects of mivacurium and atracurium during fentanyl anaesthesia

We have measured the haemodynamic effects of mivacurium 0.15and 0.2 mg kg^–1, and atracurium 0.5 mg kg^–1 administeredover 10–15 s in patients undergoing coronary artery bypasssurgery under fentanyl anaesthesia. There were no significanthaemodynamic changes in the atracurium group, other than a transientdecrease in pulmonary arterial wedge pressure. Changes in heartrate were small in all three groups. Mivacurium 0.15 mg kg^–1produced changes of only small magnitude (12% decrease in meanarterial pressure and 16% decrease in systemic vascular resistanceindex) however, mivacurium 0.2 mg kg^–1 produced a 25%reduction in mean arterial pressure, a 14% increase in cardiacindex and a 35% decrease in systemic vascular resistance index.Erythema developed in two, three and seven patients after atracurium,mivacurium 0.15mgkg^–1 and mivacurium 0.2 mg kg^–1,respectively. One patient exhibited a 54% decrease in mean arterialpressure, generalized erythema and bronchospasm after mivacurium0.2mg kg^–1. The haemodynamic changes with mivacurium suggestedhistamine release. (Br. J. Anaesth. 1995; 74: 330–332)     

罗库溴铵和阿曲库铵肌松作用的对比研究

目的 比较两种短效非去极化肌松药罗库铵在妇科腹腔镜手术全麻中的肌松作用。方法 选择妇科腹腔镜手术病人40例，术前检查无明显肝肾功能损害。随机分罗库溴铵组（Ⅰ组，n1=20例）和阿曲库铵组（Ⅱ组，n2=20例）。麻醉诱导；静注咪唑安定0.1mg/kg，芬太尼5μg/kg，琥珀胆碱1.5mg/kg，丙泊酚1.5mg/kg，经口明视插管，接Datex-OhmedaAS/3麻醉机，用TOF-guard肌松监测仪（丹麦），采用TOF刺激模式，当肌颤搐恢复至T125%时，静注罗库溴铵0.8mg/kg或阿曲库铵0.5mg/kg维持肌松；当T15%-10%时，分别追加罗库溴铵0.4mg/kg或阿曲库铵0.2mg/kg。麻醉维持丙泊酚80-120mg/h和苏太尼40-60μg/h速率用微量注射泵静脉注射，同时吸入氧化亚氮（N2O：O2为1：1）。结果 I组起效时间明显较Ⅱ组短，并且T125%时间，T190%时间以及恢复指数均较Ⅱ组短。Ⅱ组的循环变化主要表现在注药后1，3，5分钟的SBP较注射前呈明显下降，5分钟后呈回升趋势，结论 罗库溴铵比阿曲库铵肌松起效快，恢复较迅速，对循环影响小，是内腔镜手术麻醉时的良好肌松药选择。     

Comparison of atracurium and vecuronium in anaesthesia for renal transplantation

In a controlled study, equipotent doses of atracurium (20 patients) or vecuronium (22 patients) were given randomly to patients with chronic renal failure anaesthetized for renal transplantation. There were no statistically significant differences in the degree of muscle relaxation (electromyographic twitch response) and circulatory parameters. Plasma histamine concentration increased in three patients after the first dose of atracurium, but in none of the patients could any signs of allergic reactions be observed. Tracheal intubation was difficult in six patients of the atracurium group, all of whom had diabetes mellitus and varying degrees of neck stiffness. The neuromuscular block response in diabetic uraemic patients was similar to that in other uraemic patients.     

Comparison of rocuronium and vecuronium in paediatric cardiac surgery, using sevoflurane anaesthesia

Aim. The goal was to study the haemodynamic effects and intubating conditions, of rocuronium, vs. vecuronium in paediatric patients undergoing elective cardiac surgery. The haemodymanic effects and intubating conditions, of rocuronium, in children undergoing cardiac surgery, remain incompletely characterised. Methods. A double blind randomised study was conducted in 40 children with congenital heart disease, undergoing open heart surgery. Patients were divided into 2 groups — Group A received rocuronium (0.9 mgkg⁻¹) and Group B, vecuronium (0.2 mgkg⁻¹) (n=20 in each group) Intubating conditions and haemodynamic profile were assessed at 60 seconds and at 90 seconds. Neuromuscular monitoring was established before muscle relaxant administration. Anaesthesia technique standardised with sevoflurane 7–8% in addition, was used in both groups. Results. Compared with vecuronium, rocuronium was associated with shorter onset time (60.2±20.2 vs 88.6±41.2 secs; P<0.001) and clinical duration of action (34.3±8.4 vs 44.7±6.2 min, P<0.001). According to standardised, intubation scores, intubation conditions, at 90 seconds in Group A was 90% and Group B 80%. However at 60 seconds they were 80% and 40% respectively. Haemodynamic stability in both the groups was similar, although one patient in Group B showed transient bradycardia and hypotension. Conclusion. Rocuronium showed better intubating conditions than vecuronium at 60 seconds in paediatric patients undergoing open heart surgery.     

Neuromuscular effects of rocuronium in children during halothane anaesthesia

Rocuronium bromide, a nondepolarizing muscle relaxant has been shown to have a short onset and intermediate duration of action in adults and young children. We evaluated onset time, intubating conditions, as well as duration of action of rocuronium in children ages four to 12 years during nitrous oxide-halothane anaesthesia. Following a stable recording of train-of-four (TOF) impulses at the ulnar nerve, patients were given rocuronium 600 μg˙kg^?1 intravenously. We found that the time to 90% and 100% neuromuscular (N-M) block of the (TOF) was 51 ± 18 s and 66 ± 32 s respectively. Intubation was achieved at 94 ± 31 s and rated as good or excellent in all cases. Time to recovery of N-M transmission to 25%, 75% and 90% of control was 29 ± 8 min, 42 ± 14 min and 46 ± 16 min respectively. Heart rate increased ～12 BPM after drug injection, while the blood pressure remained unchanged. From our data we conclude that, as in other age groups, rocuronium has a rapid onset, intermediate duration of action in children 4–12 years of age, and appears devoid of significant side effects.     

Spirometric evaluation of respiratory activity recovery after neuromuscular block with atracurium in ambulatory surgery

We studied a group of 60 patients, undergoing day hospital operations. Neuromuscular blockade was obtained with atracurium besilatum; we made a spirometric evaluation at recovery of respiration at the end of surgeons. The comparison between actual and theoretical values shows that atracurium is a good drug for anaesthesia in day hospital surgery.     

Comparison of the effects of midazolam and thiopental on the neuromuscular response of vecuronium, atracurium, and pancuronium]

To assess the possible interactions of midazolam and thiopental with the muscular relaxants vecuronium (0.08 mg/kg), atracurium (0.5 mg/kg), and pancuronium (0.1 mg/kg), a comparative analysis was undertaken in two groups of 18 and 32 patients treated respectively with midazolam (0.3 mg/kg) and thiopental (5 mg/kg). The beginning of the effect, maximal blockade, duration of the clinical response, and the spontaneous recovery index were measured on electromyographic recordings of action potentials evoked by train of four supramaximal stimuli delivered every 20 sec on the ulnar nerve. Conditions for intubation were assessed 2 minutes after administration of muscular relaxant. There were no significant differences in neuromuscular parameters in either of the two groups of patients treated with midazolam or with thiopental independently of the relaxant drug administered.     

Neuromuscular blocking effects of rocuronium during desflurane, isoflurane, and sevoflurane anaesthesia

Purpose

To determine the magnitude of the potentiation of rocuronium by desflurane, isoflurane and sevoflurane 1.5 MAC anaesthesia.

Methods

In a prospective, randomised, study in 80 patients, the cumulative dose-effect curves for rocuronium were determined during anaesthesia with desflurane, sevoflurane and isoflurane (with N₂O 70%, 15 min steady state) or total intravenous anaesthesia (TIVA) using propofol/fentanyl. Neuromuscular block was assessed by acceleromyography (TOF-Guard®) after train-of-four (TOF) stimulation of the ulnar nerve (2Hz every 12sec, 200 μsec duration), Rocuronium was administered in increments of 100 μg·kg^?1 until first twitch (T₁) depression > 95%.

Results

Rocuronium led to more pronounced T₁ depression with desflurane or sevoflurane anaesthesia than with TIVA. The ED₅₀ and ED₉₅ were lower during desflurane (95 ± 25 and 190 ± 80 μg·kg^?1) and sevoflurane (120 ±30 and 210 ± 40 μg·kg^?1) than with TIVA (150 ± 40 and 310 ± 90 μg·kg^?1) (P < .01), while the difference was not significant for isoflurane (130 ± 40 and 250 ± 90 μg·kg^?1). Following equi-effective dosing (T₁ > 95%) the duration to 25% T₁ recovery, recovery index (25/75), and TOF_0.70 was: 13.2 ± 1.8, 12.7 ± 3.4, and 26.9 ± 5.7 min during anaesthesia with desflurane; 15.5 ± 5.0, 11.4 ± 3.8, and 31.0 ± 6.0 min with sevoflurane; 13.9 ± 4.7, 10.7 ± 3.3, and 26.3 ± 8.9 min with isoflurane; and 13.9 ± 3.9, 11.3 ± 5.7, and 27.5 ± 8,2 min with TIVA anaesthesia (P: NS).

Conclusion

Interaction of rocuronium and volatile anaesthetics resulted in augmentation of the intensity of neuromuscular block but did not result in significant effects on duration of or recovery from the block.     

Spontaneous recovery of residual neuromuscular blockade after atracurium or vecuronium during isoflurane anaesthesia

With atracurium and vecuronium, spontaneous recovery of residual neuromuscular blockade monitored electromyographically during 0.5% isoflurane anaesthesia was studied in 60 patients undergoing plastic surgery. After thiopentone, in random order, either atracurium 0.5 mg kg-1 or vecuronium 0.1 mg kg-1 was administered and isoflurane added to N2O and O2 mixture. Following spontaneous recovery of both the single twitch amplitude (T1) to 75% of the control value and the train-of-four ratio (TOF ratio) to 75%, incremental doses of the relaxant were given to maintain the T1 at less than 10%. Before the end of surgery, the blockade was again permitted to recover spontaneously. During the initial spontaneous recovery, the mean recovery time of T1 from 25% to 75% (the recovery index) with atracurium was longer (P less than 0.001) than that with vecuronium (13.2 min and 10.1 min, respectively) but, during the second recovery, the mean recovery index was shorter (P less than 0.05) with atracurium than with vecuronium (16.1 min and 19.8 min, respectively). The recovery time from T1 75% to TOF ratio 75%, indicating the recovery rate of residual neuromuscular blockade, with atracurium was about 15 min after both the initial and the second recoveries. With vecuronium, the respective recovery times were significantly (P less than 0.001) longer (25.6 min and 38.5 min, respectively). It is concluded that with vecuronium there is slower spontaneous recovery of residual neuromuscular blockade than with atracurium.     

Increased sensitivity to rocuronium and atracurium in mitochondrial myopathy

Purpose  To describe the prolonged effect of the intermediate-acting, non-depolarising neuromuscular blocking agents rocuronium and atracurium in a 29-yr-old apparently healthy woman. Clinical features  Because of abdominal pain the patient was scheduled for explorativelaparoscopic pelvic examination. General anaesthesia was induced with fentanyl, midazolam and propofol. Muscle relaxation was achieved with 0.6 mg·kg♪⁻¹ rocuronium. Anaesthesia was maintained with nitrous oxide and propofol. Two Hz train-of-four stimulation every 15 sec evoked no twitch responses until 60 min after rocuronium. Further relaxation was achieved with 0.075 mg·kg♪⁻¹ atracurium after which twitch responses recurred after 45 min. Fifteen minutes later neuromuscular blockade was successfully reversed with atropine and neostigmine. The postanaesthetic course was uneventful. Because of the increased sensitivity to rocuronium and atracurium the patient was re-evaluated postoperatively. History revealed occasional double vision, fatigue, muscle cramps, stiffness and myoglobinuria. Clinical neurological examination showed ptosis, tremor, ataxia and bradydiadochokinesia. A standardised lactate stress testing on a bicycle was pathological and, after muscle biopsy, the diagnosis of mitochondrial myopathy was established. Conclusion  An increased sensitivity to rocuronium and atracurium may occur in patients with mitochondrial myopathy. In these patients appropriate dosing of muscle relaxants and adequate monitoring of the neuromuscular’ blockade are required. If an increased sensitivity to rocuronium and atracurium occurs in an apparently healthy subject, further neurological investigations should follow.

---

Résumé Objectif  Décrire l’effet prolongé des inhibiteurs neuromusculaires non dépolarisants à action intermédiaire, rocuronium et atracurium, chez une femme de 29 ans apparemment en bonne santé. Aspects cliniques  La patiente a été admise pour un examen laparoscopique exploratoire du bassin à la suite de douleurs abdominales. L’anesthésie générale a été induite avec du fentanyl, du midazolam et du propofol. La relaxation musculaire a été obtenue avec 0,6 mg·kg♪⁻¹ de rocuronium. Lanesthésie a été maintenue avec du protoxyde d’azote et du propofol. Une stimulation de deux Hz en train-de-quatre à toutes les 15 secondes n’a pas déclenché de contraction musculaire avant 60 minutes suivant l’administration du rocuronium. Une relaxation supplémentaire a été obtenue, avec 0,075 mg·kg♪⁻¹ d’atracurium, après laquelle les contractions musculaires ont reparu 45 minutes plus tard. Après quinze minutes, le bloc neuromusculaire était renversé avec succès avec l’atropine et la néostigmine. Lévolution postanesthésique a été sans complication. La patiente a été évaluée de nouveau après l’intervention à cause de la sensibilité accrue au rocuronium. L’histoire a révélé une diplopie occasionnelle, de la fatigue, des crampes musculaires, de la raideur et de la myoglobinurie. L’examen neurologique clinique a montré de la ptose, des tremblements, de l’ataxie et de la bradydiadococinésie. Une épreuve d’effort au lactate, sur une bicyclette, s’est révélé pathologique et, après la biopsie musculaire, le diagnostic de myopathie mitochondriale a été rendu. Conclusion  Une sensibilité élevée au rocuronium et à l’atracurium peut survenir chez les patients atteints de myopathie mitochondriale. Chez ces patients, le dosage approprié de relaxants musculaires et la surveillance adéquate du bloc neuromusculaire sont nécessaires. Si une grande sensibilité au rocuronium et à l’atracurium se manifeste chez un sujet en bonne santé apparente, des examens neurologiques complémentaires devraient être fats.

     

肝移植术患者罗库溴铵不同给药方式肌松效果的比较

目的 比较肝移植术患者间断静脉注射(Ⅳ)、静脉输注(CI)和靶控输注(TCI)罗库溴铵的肌松效果.方法 拟行肝移植术的患者36例,性别不限,年龄21～63岁,体重48～80 kg,Child-Pugh评分7～9分,肝功能Child分级B或C级,随机分为3组(n=12):Ⅳ组、CI组和TCI组.采用TOF模式进行肌松监测,Ⅳ组:麻醉诱导时静脉注射罗库溴铵0.6 mg/kg,无肝前期T1恢复至25%时、无肝期和新肝期T4/T1(TOFR)恢复至25%时追加0.15 mg/kg.TCI组:麻醉诱导时靶控输注罗库溴铵,初始效应室靶浓度3μg/ml,调整靶浓度,维持T1 5%～10%;无肝期和新肝期开始时暂停TCI,随后以效应室靶浓度0.1μg/ml再次输注,调整靶浓度,维持T15%～10%.CI组:麻醉诱导时静脉注射罗库溴铵0.6 mg/kg,无肝前期以30μg·kg-1·min-1的速率开始静脉输注,调节输注速率,维持T1 5%～10%,无肝期和新肝期开始时暂停CI,随后以1μg·kg-1·min-1的速率静脉再次输注,调整输注速率,维持T15%～10%.各组于肌松达最大效应时行气管插管,于缝合腹膜后停止给药.记录麻醉诱导时罗库溴铵肌松起效时间、T1最大抑制程度和气管插管条件满意情况;记录各组无肝期T1 25%恢复时间及TOFR 25%恢复时间,新肝期停药后T125%恢复时间、TOFR 25%恢复时间、TOFR 75%恢复时间、TOFR90%恢复时间及恢复指数;记录罗库溴铵总用量.结果 与Ⅳ组比较,TCI组和CI组气管插管条件满意率、罗库溴铵总用量、麻醉诱导时罗库溴铵起效时间、T1最大抑制程度和各期肌松恢复情况差异均无统计学意义(P＞0.05).肌松效应监测图显示Ⅳ组各期罗库溴铵肌松效应波动较大,TCI组和CI组各期肌松效应较为平稳.结论 采用Ⅳ、CI和TCI给药时,肝移植术患者罗库溴铵肌松起效和恢复情况无差异,而采用TCI或CI给药时,肌松效应较Ⅳ更加平稳.     

七氟烷对糖尿病和非糖尿病患者罗库溴铵肌松效应影响的比较

目的 比较七氟烷对糖尿病和非糖尿病患者罗库溴铵肌松效应的影响.方法 择期腹部手术患者60例,年龄45～64岁,ASAⅡ级,其中Ⅱ型糖尿病患者30例,随机分为2组(n=15):异丙酚组(PD组)和七氟烷组(SD组);非糖尿病患者30例,随机分为2组(n=15):异丙酚组(PN组)和七氟烷组(SN组).静脉注射咪达唑仑、异丙酚和芬太尼行麻醉诱导后启动肌松监测,PD组和PN组静脉注射罗库溴铵0.6 mg/kg后气管插管,静脉输注异丙酚维持麻醉;SD组和SN组1%地卡因充分表面麻醉后气管插管.吸入七氟烷(呼气末浓度1.71%)10 min后静脉注射罗库溴铵0.6 mg/kg,吸入七氟烷(呼气末浓度1.71%)维持麻醉.记录肌松起效时间、维持时间和恢复指数.于静脉注射罗库溴铵后10、20、30、40、50、60、70、80、90、100、110、120 min时记录T1/T0比值及TOF比值(T4T1比值).结果 PN组与PD组、SN组与SD组、PD组与SD组间罗库溴铵起效时间、维持时间比较差异无统计学意义(P>0.05).与SN组和PD组比较,SD组恢复指数延长(P<0.05).静脉注射罗库溴铵后60～120 min,SD组T1/T0比值和TOF比值较PD组降低(P<0.05);静脉注射罗库溴铵后80～120 min,SD组TOF比值较SN组降低(P<0.05).结论 与非糖尿病患者相比,七氟烷对糖尿病患者罗库溴铵肌松效应的强化作用进一步增强.     

A microelectrode study of the effects of atracurium on neuromuscular transmission

Using standard microelectrode recording techniques, we studied the effects of atracurium on neuromuscular transmission in a concentration range between 10(-13) and 10(-5) M in the rat diaphragm. Both intact and cut diaphragm preparations were used. Atracurium produced no significant alteration of miniature endplate potential (MEPP) frequency (P greater than 0.05). Increasing concentrations of atracurium (10(-6)-10(-5) M) caused a linear decrease in MEPP amplitude from 70.5 +/- 2.3% to 28.0 +/- 2.5% of baseline levels (P less than 0.05). In the cut diaphragm preparation, atracurium increased the degree of rundown and decreased quantum content of the endplate potential (EPP). The above observations suggest that atracurium interferes with neuromuscular transmission by, first of all, producing cholinergic receptor block and secondly, producing frequency-dependent inhibition of release of acetylcholine from the nerve terminal.     

A double-blind, randomized comparison of low-dose rocuronium and atracurium in a desflurane anesthetic

STUDY OBJECTIVES: To compare the neuromuscular and hemodynamic effects of rocuronium and atracurium when administered during a desflurane-based anesthetic. DESIGN: Randomized, double-blind clinical trial. PATIENTS: 51 adult ASA physical status I and II patients scheduled for general surgical operations. SETTING: University-based NCI-designated cancer center. INTERVENTIONS: Patients received either 0.45 mg/kg rocuronium (n = 28) or atracurium 0.5 mg/kg (n = 23). Induction of anesthesia was accomplished by 2 microg/kg fentanyl intravenously (IV) and 1.5 mg/kg propofol IV and maintained by a nitrous oxide/oxygen desflurane anesthetic. MEASUREMENTS AND MAIN RESULTS: A neuromuscular monitor was used at the adductor pollicis to monitor and record twitch response to train-of-four electrical stimulation. Baseline heart rate (HR) and blood pressure (BP) were measured and again at 2, 5, 10, and 15 minutes after muscle relaxant administration. Patients in the rocuronium group were found to have shorter times to 80%T(1)depression (109 +/- 53 vs. 135 +/- 47 sec), although those differences did not reach statistical significance (p = 0.07). Percent of the first twitch (T(1) ) was significantly lower in the patients receiving rocuronium at 60 seconds (53 +/- 24 vs. 73 +/- 27 sec; p = 0.006) and 90 seconds (25 +/- 22 vs. 47 +/- 29 sec; p = 0.003) than in the patients receiving atracurium. Duration was shorter in rocuronium-treated patients (25% T(1) recovery = 32 +/- 12 vs. 54 +/- 14 min; p < 0.001) than the patients receiving atracurium. Intubation scores were better at 60 seconds after muscle relaxant administration in the rocuronium group. No significant differences in HR or BP were seen between the patients in the two groups. CONCLUSIONS: Rocuronium at a dose of 0.45 mg/kg possesses a fairly rapid onset of neuromuscular blockade and has short:intermediate duration of action when used with a desflurane anesthetic. This quality makes it a desirable drug for operations of relatively short duration. Rocuronium at a dose of 0.45 mg/kg has a faster onset and shorter duration than atracurium, at 0.5 mg/kg, when used with a desflurane anesthetic.     

Histamine-release haemodynamic changes produced by rocuronium, vecuronium, mivacurium, atracurium and tubocurarine

We have examined the effects of different benzyl-isoquinolinium and steroidal neuromuscular blocking compounds on plasma concentrations of histamine, heart rate and arterial pressure in surgical patients. A single, rapid (5-s) bolus of mivacurium 0.2 mg kg-1, atracurium 0.6 mg kg-1, tubocurarine 0.5 mg kg-1, vecuronium 0.1 mg kg-1 or rocuronium 0.6 mg kg-1 was administered to 75 patients (n = 15 in each group). Anaesthesia was induced with thiopentone 6 mg kg-1 i.v. and maintained with isoflurane and 70% nitrous oxide in oxygen. Venous blood samples were obtained before induction, 1 min after thiopentone and 1, 3 and 5 min after administration of the neuromuscular blocking drug. Mivacurium, atracurium and tubocurarine caused 370%, 234% and 252% increases in plasma histamine concentrations at 1 min, respectively. Corresponding values at 3 min were 223%, 148% and 157%, respectively. These changes were significant (P < 0.01) at 1 and 3 min. In contrast, the rocuronium and vecuronium groups had no significant changes in either plasma histamine concentrations or haemodynamic variables.